Extrait

The primary objective of part A is to investigate the hemodynamic and subjective effects on dyspnoea and well-being of 3 doses of BAY 58-2667 given intravenously over 2 hours per dose step in a dose escalation manner. In total, 3 dose steps per subject are planned. The primary objective of part B is to investigate the hemodynamic effect of BAY 58-2667 given intravenously over 6 hours.

Critère d'inclusion

• Critically ill patients, male and female, admitted to hospital with decompensated chronic congestive heart failure and clinical indication for parenteral pharmacotherapy with invasive hemodynamic monitoring and a PCWP of higher or equal 18 mmHg

Liens

• ictrp
• euctr